Chapman J - Search Results

1

Pharmacologic management of neuropsychiatric lupus.

Kivity S, Baker B, Arango MT, Chapman J, Shoenfeld Y. Kivity S, et al. Among authors: chapman j. Expert Rev Clin Pharmacol. 2016;9(1):103-8. doi: 10.1586/17512433.2016.1111137. Epub 2015 Nov 11. Expert Rev Clin Pharmacol. 2016. PMID: 26559084 Review.

2

Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes.

Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD. Chapman J, et al. Lupus. 1999;8(2):127-33. doi: 10.1191/096120399678847524. Lupus. 1999. PMID: 10192507

3

[Central nervous system involvement in antiphospholipid syndrome].

Shro S, Chapman J, Shoenfeld Y. Shro S, et al. Among authors: chapman j. Harefuah. 2001 Jan;140(1):40-4. Harefuah. 2001. PMID: 11242899 Review. Hebrew. No abstract available.

4

Hyperactivity in a mouse model of the antiphospholipid syndrome.

Katzav A, Pick CG, Korczyn AD, Oest E, Blank M, Shoenfeld Y, Chapman J. Katzav A, et al. Among authors: chapman j. Lupus. 2001;10(7):496-9. doi: 10.1191/096120301678416060. Lupus. 2001. PMID: 11480848

5

Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS).

Katzav A, Kloog Y, Korczyn AD, Niv H, Karussis DM, Wang N, Rabinowitz R, Blank M, Shoenfeld Y, Chapman J. Katzav A, et al. Among authors: chapman j. Clin Exp Immunol. 2001 Dec;126(3):570-7. doi: 10.1046/j.1365-2249.2001.01674.x. Clin Exp Immunol. 2001. PMID: 11737078 Free PMC article.

6

Neurological and neuroendocrine-cytokine inter-relationship in the antiphospholipid syndrome.

Chapman J, Shoenfeld Y. Chapman J, et al. Ann N Y Acad Sci. 2002 Jun;966:415-24. doi: 10.1111/j.1749-6632.2002.tb04242.x. Ann N Y Acad Sci. 2002. PMID: 12114299 Review.

7

Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies.

Shrot S, Katzav A, Korczyn AD, Litvinju Y, Hershenson R, Pick CG, Blank M, Zaech J, Shoenfeld Y, Sirota P, Chapman J. Shrot S, et al. Among authors: chapman j. Lupus. 2002;11(11):736-43. doi: 10.1191/0961203302lu255oa. Lupus. 2002. PMID: 12475004

8

Inhibition of ras by farnesylthiosalicylate significantly reduces the levels of autoantibodies in two animal models of the antiphospholipid syndrome.

Katzav A, Kloog Y, Korczyn AD, Molina V, Blank M, Shoenfeld Y, Chapman J. Katzav A, et al. Among authors: chapman j. Immunobiology. 2003;207(1):47-50. doi: 10.1078/0171-2985-00208. Immunobiology. 2003. PMID: 12638903

9

10th International Congress on Antiphospholipid Antibodies--summary.

Zandman-Goddard G, Blank M, Sherer Y, Ehrenfeld M, Chapman J, Orbach H, Gilburd B, Krause I, Shoenfeld Y. Zandman-Goddard G, et al. Among authors: chapman j. Autoimmun Rev. 2003 Mar;2(2):79-85. doi: 10.1016/s1568-9972(02)00142-8. Autoimmun Rev. 2003. PMID: 12848963

10

Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer.

Shoenfeld Y, Nahum A, Korczyn AD, Dano M, Rabinowitz R, Beilin O, Pick CG, Leider-Trejo L, Kalashnikova L, Blank M, Chapman J. Shoenfeld Y, et al. Among authors: chapman j. Lupus. 2003;12(6):436-42. doi: 10.1191/0961203303lu409oa. Lupus. 2003. PMID: 12873044

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,203 results

Search Page